Treatment of lipodermatosclerosis with oxandrolone in a patient with stanozolol-induced hepatotoxicity.
Segal
S
S
Cooper
J
J
Bolognia
J
J
D045930:Anabolic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury; D005260:Female; D006801:Humans; D017495:Hyperpigmentation / Q000209:etiology / Q000473:pathology*; D008875:Middle Aged; D010074:Oxandrolone / Q000627:therapeutic use*; D012594:Scleroderma, Localized / Q000188:drug therapy* / Q000473:pathology; D013197:Stanozolol / Q000009:adverse effects* / Q000627:therapeutic use; D014689:Venous Insufficiency / Q000150:complications*
D045930:Anabolic Agents; D013197:Stanozolol; D010074:Oxandrolone